Industry Satellite Symposia

These presentations were selected by the 2022 Multidisciplinary Symposium in Head and Neck Oncology Steering Committee as an independent educational activity held in conjunction with the 2022 Multidisciplinary Symposium in Head and Neck Oncology. These presentations are not sponsored or endorsed by any of the co-sponsoring organizations of the symposium.

Dinner or other food and beverages may be provided by the companies, which may subject you to reporting under the Federal Sunshine Act (the Open Payments Program) or other state laws.

Opportunities in Head and Neck Cancer: Promising Phase II Data Combining an Antagonist of IAPs with Chemoradiotherapy

Thursday, February 24, 2022
5:30 p.m. - 6:30 p.m.
Grand Canyon Ballroom 9 & 10

Faculty
Ezra Cohen, MD
Associate Director
Clinical Science
Moores Cancer Center
University of California, San Diego

Robert Ferris, MD, PhD
Director
Associate Vice Chancellor for Cancer Research
Hillman Professor of Oncology
UPMC Hillman Cancer Center
Pittsburgh

Jonathan Schoenfeld, MD, MPH
Senior Physician
Dana-Farber Cancer Institute and Brigham and Women’s Hospital
Dana-Farber / Harvard Cancer Center
Boston

Credit Designation
This Non-CME Informational/Educational Program refers to any educational activity that is independently organized, held in conjunction with the 2022 Multidisciplinary Head and Neck Cancers Symposium and does not carry Continuing Medical Education (CME) credit.

Supporter Statement
This event is supported independently by Merck KGaA Darmstadt Germany. To learn more about Merck KGaA Darmstadt Germany, visit https://www.merckgroup.com/.

Who's In Your Waiting Room? Multidisciplinary Perspectives on the Management of CSCC of the Head and Neck

Activity Overview
This Medscape Live symposium will provide clinicians with an immersive, case-based educational experience to improve clinicians’ ability to individualize care for patients with cutaneous squamous cell carcinoma of the head and neck. A simulated waiting room will feature three diverse patients, with discussion about their management from a multidisciplinary team perspective, including a medical oncologist, surgeon, pathologist and patient advocate. Please come with your most pressing questions for our expert faculty!

Learning Objectives
Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Characteristics of CSCC of the head and neck
  • Clinical evidence evaluating systemic therapies used to manage patients with CSCC of the head and neck
• Have greater competence related to
  • Individualizing care for patients with CSCC of the head and neck
  • Mitigating potential adverse events associated with the use of systemic therapies for CSCC of the head and neck
• Demonstrate greater confidence in their ability to
  • Coordinate the care of patients with CSCC of the head and neck with the multidisciplinary team

Faculty
Theresa Guo, MD
Assistant Professor, Division of Otolaryngology Head and Neck Surgery
Gleiberman Early Career Faculty Fellow
Hanna and Mark Gleiberman Head and Neck Cancer Center
University of California, San Diego
San Diego

Nicole A. Cipriani, MD
Associate Professor of Pathology
Medical Director of Gross Pathology
Director of Anatomic Pathology Informatics
The University of Chicago
Chicago

Nabil F. Saba, MD, FACP
Professor and Vice Chair, Hematology and Medical Oncology
The Lynne and Howard Halpern Chair in Head and Neck Cancer Research
Co-Director
Head and Neck Cancer Multidisciplinary Program
Winship Cancer Institute
Emory University
Atlanta

Accreditation Statement
In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

For Physicians
Medscape LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an independent medical educational grant from Merck & Co. Inc., Regeneron Pharmaceuticals Inc. and Sanofi Genzyme.

The 2022 Multidisciplinary Head and Neck Cancers Symposium Steering Committee have reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposia (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2022 Multidisciplinary Head and Neck Cancers Symposium program. ISS and non-CME ISS refers to any educational activity that is independently organized and held in conjunction with the 2022 Multidisciplinary Head and Neck Cancers Symposium. This includes any educational activity that carries Continuing Medical Education (CME) credit not sponsored by ASTRO.